We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
- Authors
Takaura, Kenta; Kurosaki, Masayuki; Inada, Kento; Kirino, Sakura; Yamashita, Kouji; Muto, Tomohiro; Osawa, Leona; Sekiguchi, Shuhei; Hayakawa, Yuka; Higuchi, Mayu; Kaneko, Shun; Maeyashiki, Chiaki; Tamaki, Nobuharu; Yasui, Yutaka; Itakura, Jun; Tsuchiya, Kaoru; Nakanishi, Hiroyuki; Takahashi, Yuka; Izumi, Namiki
- Abstract
Background and aim: The long-term prognosis of hepatocellular carcinoma (HCC) treated at a very-early-stage (the Barcelona Clinical Liver Cancer (BCLC) classification stage 0) was unclear, especially in terms of background liver disease. Methods: This single-center, retrospective study included 302 patients with BCLC stage 0 HCC treated with radiofrequency ablation (RFA) and followed for at least six months. We examined the impact of background liver disease on overall survival and recurrence. Results: The median age was 72 (range; 36–91) years; the median tumor diameter was 15 (range; 8–20) mm. The etiologies of background liver disease were hepatitis B virus infection (HBV) in 24 cases, hepatitis C virus infection (HCV) in 195 cases, and non-viral (NBNC) in 83 cases. Among the patients with HCV, 63 had achieved sustained virological response (SVR) by antiviral therapy (HCV SVR) before developing HCC (n = 37) or after HCC treatment (n = 26), and 132 had active HCV infection (HCV non-SVR). The median overall survival was 85 (95% CI; 72–98) months, and the median recurrence-free survival was 26 (95% CI; 20–30) months. Active infection with hepatitis C virus negatively contributed to overall survival (HR 2.91, 95% CI 1.31–3.60, p = 0.003) and recurrence-free survival (HR 1.47, 95% CI 1.06–2.05, p = 0.011). Conclusions: The prognosis of RFA treatment for very early-stage HCC was favorable. Achieving SVR in hepatitis C was important for further prognosis improvement.
- Subjects
HEPATITIS C; PROGRESSION-free survival; HEPATITIS B; LIVER diseases; ABLATION techniques; PROGNOSIS; VIRUS diseases
- Publication
PLoS ONE, 2022, Vol 17, Issue 2, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0264075